Spastic paraplegia gene 7 in patients with spasticity and/or optic neuropathy

…, G Sole, A Destée, JM Mayer, B Fontaine, J Seze… - Brain, 2012 - academic.oup.com
Mutations in the spastic paraplegia 7 (SPG7) gene encoding paraplegin are responsible for
autosomal recessive hereditary spasticity. We screened 135 unrelated index cases, selected …

[HTML][HTML] Excess mortality in patients with multiple sclerosis starts at 20 years from clinical onset: data from a large-scale French observational study

…, M Debouverie, M Clanet, B Brochet, J Sèze… - PloS one, 2015 - journals.plos.org
Background Recent studies in multiple sclerosis (MS) showed longer survival times from
clinical onset than older hospital-based series. However estimated median time ranges widely, …

Myelin-oligodendrocyte glycoprotein antibody-associated disease

…, T Chitnis, O Ciccarelli, K Deiva, J De Sèze… - The Lancet …, 2021 - thelancet.com
Myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently
identified autoimmune disorder that presents in both adults and children as CNS demyelination…

MRI characteristics of neuromyelitis optica spectrum disorder: an international update

…, N Asgari, J Palace, EC Klawiter, DK Sato, J de Seze… - Neurology, 2015 - AAN Enterprises
Since its initial reports in the 19th century, neuromyelitis optica (NMO) had been thought to
involve only the optic nerves and spinal cord. However, the discovery of highly specific anti–…

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

…, A Czlonkowska, AM da Silva, J de Sa, J de Seze… - The Lancet, 2018 - thelancet.com
Background No treatment has consistently shown efficacy in slowing disability progression
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …

[HTML][HTML] Sensitivity of infectious SARS-CoV-2 B. 1.1. 7 and B. 1.351 variants to neutralizing antibodies

…, F Schortgen, L Yahyaoui, M Gonzalez, J De Sèze… - Nature medicine, 2021 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.7 and B.1.351 variants
were first identified in the United Kingdom and South Africa, respectively, and have since …

[HTML][HTML] Ocrelizumab versus placebo in primary progressive multiple sclerosis

…, DL Arnold, A Bar-Or, G Comi, J De Seze… - New england journal …, 2017 - Mass Medical Soc
Background An evolving understanding of the immunopathogenesis of multiple sclerosis
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

…, JL Bennett, P Cabre, W Carroll, T Chitnis, J De Seze… - Neurology, 2015 - AAN Enterprises
Neuromyelitis optica (NMO) is an inflammatory CNS syndrome distinct from multiple
sclerosis (MS) that is associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). …

Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients

S Delalande, J de Seze, AL Fauchais, E Hachulla… - Medicine, 2004 - journals.lww.com
Neurologic involvement occurs in approximately 20% of patients with primary Sjögren syndrome
(SS). However, the diagnosis of SS with neurologic involvement is sometimes difficult, …

Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis

…, DA Laplaud, S Vukusic, C Lubetzki, J De Sèze - JAMA …, 2020 - jamanetwork.com
Importance Risk factors associated with the severity of coronavirus disease 2019 (COVID-19)
in patients with multiple sclerosis (MS) are unknown. Disease-modifying therapies (DMTs) …